{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:36:03Z","timestamp":1792802163815,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AR041215"],"award-info":[{"award-number":["AR041215"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jid.2024.09.017","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T15:47:20Z","timestamp":1731426440000},"page":"1294-1304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recent Advances in Juvenile Dermatomyositis: Moving toward Integration of Myositis-Specific Antibody Clinical Phenotypes, IFN-Driven Pathogenesis, and Targeted Therapies"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0361-9234","authenticated-orcid":false,"given":"Kristen L.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-2718","authenticated-orcid":false,"given":"Yvonne E.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Ann","family":"Vleugels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7760-2411","authenticated-orcid":false,"given":"Dominic O.","family":"Co","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0595-6533","authenticated-orcid":false,"given":"Hanna","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-9958","authenticated-orcid":false,"given":"Sara E.","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0468-9568","authenticated-orcid":false,"given":"Lisa M.","family":"Arkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2024.09.017_bib1","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib2","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2024.09.017_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","article-title":"Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 9","key":"10.1016\/j.jid.2024.09.017_bib4","first-page":"2576","article-title":"Rapid onset of response in adult dermatomyositis patients receiving anti-interferon \u03b2 (PF-06823859): results of a phase 2, double-blind, randomized, placebo-controlled study","volume":"75","author":"Aggarwal","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nm1590","article-title":"TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity","volume":"13","author":"Baccala","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2024.09.017_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Bellutti Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2024.09.017_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2022.3917","article-title":"Apremilast in recalcitrant cutaneous dermatomyositis: a nonrandomized controlled trial","volume":"158","author":"Bitar","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.09.017_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fonc.2018.00287","article-title":"\"Do We Know Jack\" about JAK? A closer look at JAK\/STAT signaling pathway","volume":"8","author":"Bousoik","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2024.09.017_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13075-020-02164-5","article-title":"Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients","volume":"22","author":"Campanilho-Marques","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2024.09.017_bib10","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.jid.2020.12.032","article-title":"Myeloid dendritic cells are major producers of IFN-\u03b2 in dermatomyositis and may contribute to hydroxychloroquine refractoriness","volume":"141","author":"Chen","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.017_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2024.09.017_bib12","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaci.2021.07.028","article-title":"JAK inhibition in the type I interferonopathies","volume":"148","author":"Crow","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"22","author":"Crow","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/art.42450","article-title":"Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy","volume":"75","author":"Curiel","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib15","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.39753","article-title":"Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis","volume":"68","author":"Deakin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2217\/ijr.14.46","article-title":"Progress and prognosis in juvenile dermatomyositis","volume":"9","author":"Dvergsten","year":"2014","journal-title":"Int J Clin Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib17","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/S0140-6736(08)60955-1","article-title":"Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood","volume":"371","author":"Feldman","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2024.09.017_bib18","first-page":"470","article-title":"Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis","volume":"55","author":"Gitiaux","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jid.2024.09.017_bib19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/kem359","article-title":"Clinical associations of autoantibodies to a p155\/140 kDa doublet protein in juvenile dermatomyositis","volume":"47","author":"Gunawardena","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jid.2024.09.017_bib20","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jid.2024.09.017_bib21","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s00296-022-05176-3","article-title":"New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review","volume":"42","author":"Holzer","year":"2022","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jid.2024.09.017_bib22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nri1900","article-title":"IRFs: master regulators of signalling by toll-like receptors and cytosolic pattern-recognition receptors","volume":"6","author":"Honda","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib23","article-title":"Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on Type I interferon system","volume":"8","author":"Hu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jid.2024.09.017_bib24","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/keac399","article-title":"Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis","volume":"62","author":"Huang","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jid.2024.09.017_bib25","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.09.017_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3899\/jrheum.160688","article-title":"Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash","volume":"44","author":"Huber","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/acr.22212","article-title":"Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies","volume":"66","author":"Huber","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jid.2024.09.017_bib28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/jir.1987.7.429","article-title":"Virus interference. I. The interferon","volume":"7","author":"Isaacs","year":"1987","journal-title":"1957. J Interferon Res"},{"key":"10.1016\/j.jid.2024.09.017_bib29","first-page":"450","article-title":"Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy","volume":"63","author":"Isenberg","year":"1986","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13075-018-1737-2","article-title":"Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis","volume":"20","author":"Ishikawa","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2024.09.017_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3389\/fimmu.2019.00325","article-title":"Regulating IRFs in IFN driven disease","volume":"10","author":"Jefferies","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib33","first-page":"1718","article-title":"Interferon-gamma inhibits proliferation, differentiation, and creatine kinase activity of cultured human muscle cells. II. A possible role in myositis","volume":"20","author":"Kalovidouris","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/BOR.0000000000000816","article-title":"Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy","volume":"33","author":"Kim","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2020-218690","article-title":"Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis","volume":"80","author":"Kim","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2024.09.017_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-020-02160-9","article-title":"Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies","volume":"22","author":"Kim","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2024.09.017_bib38","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/jid.2012.54","article-title":"Gottron's papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature","volume":"132","author":"Kim","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.017_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-016-0134-0","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease","volume":"15","author":"Kim","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jid.2024.09.017_bib40","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","article-title":"Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis","volume":"54","author":"Kobayashi","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jid.2024.09.017_bib41","first-page":"275","article-title":"Potential role of type I interferon\/IP-10 axis in the pathogenesis of anti-MDA5 antibody-positive dermatomyositis","volume":"41","author":"Kokuzawa","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib42","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.jid.2024.09.017_bib43","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1136\/ard.2011.153718","article-title":"Efficacy of intravenous Ig therapy in juvenile dermatomyositis","volume":"70","author":"Lam","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2024.09.017_bib44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jdcr.2023.09.043","article-title":"Efficacy of topical ruxolitinib for cutaneous dermatomyositis","volume":"45","author":"Lanis","year":"2024","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2024.09.017_bib45","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.4049\/jimmunol.176.4.2074","article-title":"Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN","volume":"176","author":"Le Bon","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib46","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study","volume":"60","author":"Le Voyer","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jid.2024.09.017_bib47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-019-0871-4","article-title":"Juvenile dermatomyositis\u2014clinical phenotypes","volume":"21","author":"Li","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jid.2024.09.017_bib48","article-title":"Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis","author":"Liang","year":"2020","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jid.2024.09.017_bib91","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1136\/annrheumdis-2015-207762","article-title":"Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis","volume":"75","author":"Lintner","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"3 Pt 1","key":"10.1016\/j.jid.2024.09.017_bib96","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1006\/clim.2001.5212","article-title":"Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis","volume":"103","author":"Lutz","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib49","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/rheumatology\/keaa429","article-title":"Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America","volume":"60","author":"Mamyrova","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jid.2024.09.017_bib90","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1002\/art.22216","article-title":"Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians","volume":"54","author":"Mamyrova","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2024.09.017_bib92","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1002\/art.24039","article-title":"Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis","volume":"58","author":"Mamyrova","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2024.09.017_bib50","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2024.09.017_bib51","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1136\/annrheumdis-2020-217522","article-title":"Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis","volume":"79","author":"Megremis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2024.09.017_bib52","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.11122","article-title":"US incidence of juvenile dermatomyositis, 1995\u20131998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry","volume":"49","author":"Mendez","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2024.09.017_bib53","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2021.07.003","article-title":"Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers","volume":"86","author":"Min","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.09.017_bib54","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/CMR.00046-08","article-title":"Pathogen recognition and inflammatory signaling in innate immune defenses","volume":"22","author":"Mogensen","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jid.2024.09.017_bib55","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib94","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1542\/peds.2010-3022","article-title":"Familial aggregation of autoimmune disease in juvenile dermatomyositis","volume":"127","author":"Niewold","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jid.2024.09.017_bib56","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2024.09.017_bib57","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12969-018-0299-9","article-title":"Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis","volume":"16","author":"Orandi","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jid.2024.09.017_bib93","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11926-996-0007-5","article-title":"Juvenile dermatomyositis: the association of the TNF\u03b1-308A allele and disease chronicity","volume":"3","author":"Pachman","year":"2001","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jid.2024.09.017_bib58","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8","article-title":"TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications","volume":"43","author":"Pachman","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2024.09.017_bib59","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12969-023-00903-x","article-title":"Nailfold capillary density in 140 untreated children with juvenile dermatomyositis: an indicator of disease activity","volume":"21","author":"Pachman","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jid.2024.09.017_bib60","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib61","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fped.2018.00284","article-title":"The vasculopathy of juvenile dermatomyositis","volume":"6","author":"Papadopoulou","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jid.2024.09.017_bib62","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jid.2021.02.748","article-title":"Highly multiplexed mass cytometry identifies the immunophenotype in the skin of dermatomyositis","volume":"141","author":"Patel","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.09.017_bib95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2249.2000.01266.x","article-title":"Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies","volume":"121","author":"Rider","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib63","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jid.2024.09.017_bib64","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nrrheum.2011.139","article-title":"Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis","volume":"7","author":"Robinson","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib65","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/acr.22198","article-title":"Pilot study of etanercept in patients with refractory juvenile dermatomyositis","volume":"66","author":"Rouster-Stevens","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jid.2024.09.017_bib66","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jid.2024.09.017_bib67","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jid.2024.09.017_bib68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11926-021-01023-9","article-title":"COVID-19 and myositis: what we know so far","volume":"23","author":"Saud","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jid.2024.09.017_bib69","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.jid.2024.09.017_bib70","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib71","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-stimulated genes: what do they all do?","volume":"6","author":"Schoggins","year":"2019","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.jid.2024.09.017_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2024.07.1491","article-title":"Anifrolumab in recalcitrant cutaneous dermatomyositis: a multicenter retrospective cohort study [e-pub ahead of print]","author":"Shaw","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.09.017_bib73","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamadermatol.2023.4744","article-title":"Rapid improvement in recalcitrant cutaneous juvenile dermatomyositis with anifrolumab treatment","volume":"160","author":"Shaw","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.09.017_bib74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12969-022-00785-5","article-title":"Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance","volume":"21","author":"Sherman","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jid.2024.09.017_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.899526","article-title":"Autoimmune skin disease exacerbations following COVID-19 vaccination","volume":"13","author":"Sprow","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib76","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/art.42526","article-title":"The Type I interferon signature reflects multiple phenotypic and activity measures in dermatomyositis","volume":"75","author":"Tabata","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib77","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2024.09.017_bib78","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jid.2024.09.017_bib79","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jid.2024.09.017_bib80","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103420","article-title":"IFN-\u03b3: an overlooked cytokine in dermatomyositis with anti-MDA5 antibodies","volume":"22","author":"Thuner","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jid.2024.09.017_bib82","article-title":"Short-term effectiveness of baricitinib in children with refractory and\/or severe juvenile dermatomyositis","volume":"10","author":"Wang","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jid.2024.09.017_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102234","article-title":"Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study","volume":"64","author":"Werth","year":"2023","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.jid.2024.09.017_bib84","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.3389\/fimmu.2018.02951","article-title":"Systemic and tissue inflammation in juvenile dermatomyositis: from pathogenesis to the quest for monitoring tools","volume":"9","author":"Wienke","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.09.017_bib85","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2024.09.017_bib86","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.berh.2017.12.003","article-title":"Juvenile dermatomyositis: latest advances","volume":"31","author":"Wu","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jid.2024.09.017_bib87","doi-asserted-by":"crossref","DOI":"10.1080\/08916934.2023.2220984","article-title":"Patients with dermatomyositis shared partially similar transcriptome signature with COVID-19 infection","volume":"56","author":"Yang","year":"2023","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jid.2024.09.017_bib88","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","article-title":"Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications","volume":"13","author":"Ye","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2024.09.017_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24631","article-title":"Activation of cGAS-STING pathway - a possible cause of myofiber atrophy\/necrosis in dermatomyositis and immune-mediated necrotizing myopathy","volume":"36","author":"Zhou","year":"2022","journal-title":"J Clin Lab Anal"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24021833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24021833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T01:41:47Z","timestamp":1780278107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X24021833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0022202X24021833"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2024.09.017","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advances in Juvenile Dermatomyositis: Moving toward Integration of Myositis-Specific Antibody Clinical Phenotypes, IFN-Driven Pathogenesis, and Targeted Therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2024.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Society for Investigative Dermatology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}